Portfolio Adjustments: Cathie Wood's Ark Invest has reduced its holdings in several biotech companies, including 10X Genomics and Crispr Therapeutics, indicating a shift away from volatile biotech stocks towards more stable growth sectors.
Investment in Veracyte: Ark made a significant investment in Veracyte, purchasing over 665,690 shares, which saw a strong earnings report that exceeded expectations, leading to a 16% stock surge.
Roku Stake Reduction: The firm also sold more than 1.1 million shares of Roku as part of a strategy to trim its portfolio, influenced by ongoing legal issues facing the company.
Analyst Consensus on Veracyte: Analysts maintain a Moderate Buy consensus on Veracyte, with an average 12-month price target suggesting a potential downside from the current price, reflecting cautious optimism about the stock's future performance.
Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is 9.25 USD with a low forecast of 7.25 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is 9.25 USD with a low forecast of 7.25 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.570
Low
7.25
Averages
9.25
High
11.25
Current: 5.570
Low
7.25
Averages
9.25
High
11.25
Lake Street
Buy
maintain
Al Analysis
2025-09-17
Reason
Lake Street
Price Target
Al Analysis
2025-09-17
maintain
Buy
Reason
Lake Street raised the firm's price target on Strata Critical Medical to $7.25 from $6.50 and keeps a Buy rating on the shares. The firm is \"highly supportive\" of the announced acquisition of Keystone Perfusion Services for $124M pre-earnout, as it successfully addresses a concern of how post-Passenger Strata could truly deploy its massive $235M pro forma cash position in a material way via M&A, the analyst tells investors in a research note.
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
